SENSEONICS Aktie

>SENSEONICS Aktienkurs

4.76 EUR -1.2% (TradegateBSX)

Ask: 5 EUR / 995 Stück

Bid: 4.88 EUR / 1027 Stück

Tagesumsatz: 301 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SENSEONICS Aktie über LYNX handeln

Intraday

1 Jahr

>SENSEONICS Performance

1 Woche: -7,1%

1 Monat: -25,0%

3 Monate: -17,9%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: -1,2%

>SENSEONICS Aktie

Name:

SENSEONICS HLGS.INC. NEW

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US81727U3032 / A41MRZ

Symbol/ Ticker:

6L60 (Frankfurt)

Kürzel:

FRA:6L60, ETR:6L60, 6L60:GR

Index:

Webseite:

https://www.senseonics.co..

Profil:

Senseonics Holdings, Inc. is a medical technology company specializing in innovative glucose monitoring systems designed to improve diabetes management. Its flagship products, the Eversense 365 and Ev..
>Volltext..

Marktkapitalisierung:

206.35 Mio. EUR

Unternehmenswert:

160.88 Mio. EUR

Umsatz:

30.88 Mio. EUR

EBITDA:

-58.53 Mio. EUR

Nettogewinn:

-60.54 Mio. EUR

Gewinn je Aktie:

-1.48 EUR

Schulden:

36.24 Mio. EUR

Liquide Mittel:

35.52 Mio. EUR

Operativer Cashflow:

-52.15 Mio. EUR

Bargeldquote:

3.87

Umsatzwachstum:

38.29%

Gewinnwachstum:

22.51%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SENSEONICS

Letzte Datenerhebung:

15.03.26

>SENSEONICS Kennzahlen

Aktien/ Unternehmen:

Aktien: 41.77 Mio. St.

Frei handelbar: 89.21%

Leerverk. Aktien: -

Rückkaufquote: -42.76%

Mitarbeiter: 130

Umsatz/Mitarb.: 0.24 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 231.84%

Bewertung:

KGV: -

KGV lG: -

KUV: 6.31

KBV: 3.87

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 44.71%

Gewinnmarge: -196.03%

Operative Marge: -193.83%

Managementeffizenz:

Gesamtkaprendite: -60.97%

Eigenkaprendite: -168.27%

>SENSEONICS Peer Group

Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Diabetes- & Adipositas- Behandlung

>SENSEONICS Chart & Kurs - Tradegate

>SENSEONICS News

03.03.26 - 17:45	Wall Street Analysts Predict a 124.49% Upside in Senseonics (SENS): Here′s What You Should Know (Zacks)
	The consensus price target hints at a 124.5% upside potential for Senseonics (SENS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

03.03.26 - 02:30	Senseonics targets $58M–$62M 2026 revenue as company integrates sales operations and accelerates direct-to-consumer strategy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.26 - 01:00	Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
	Senseonics (SENS) delivered earnings and revenue surprises of -7.80% and +0.70%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

03.03.26 - 00:24	Senseonics (SENS) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

02.03.26 - 23:48	Protokoll des Earnings Call: Senseonics Q4 2025 mit gemischten Ergebnissen (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.03.26 - 22:06	Senseonics reports Q4 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.03.26 - 22:03	Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire EN)
	Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year...

27.02.26 - 23:39	Senseonics Q4 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.02.26 - 14:30	SENS Eversense 365 Integrated With twiist Gains Full Availability (Zacks)
	Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage....

19.02.26 - 14:03	Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365 (GlobeNewswire EN)
	The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes...

06.02.26 - 19:45	All You Need to Know About Senseonics (SENS) Rating Upgrade to Buy (Zacks)
	Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

02.02.26 - 14:30	Senseonics (SENS) Moves 5.3% Higher: Will This Strength Last? (Zacks)
	Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

30.01.26 - 19:45	SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval (Zacks)
	Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook....

29.01.26 - 22:03	Senseonics Receives European Approval for Eversense 365, World′s Longest-lasting Continuous Glucose Monitor (GlobeNewswire EN)
	GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system....

28.01.26 - 22:09

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire EN)

GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah....

12.01.26 - 14:57	Senseonics reports preliminary unaudited revenue Q4 revenue of ~$14.2M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 18:15	SENS Stock Up as Eversense 365 Enters AID Market With twiist System (Zacks)
	Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system....

08.01.26 - 22:03	Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System (GlobeNewswire EN)
	twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM...

13.11.25 - 00:24	Senseonics auf der Stifel 2025: Direktvertriebsmodell soll Wachstumsaussichten verbessern/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 15:16	Senseonics announces transfer to Nasdaq (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wir sind ebensowenig Herren unserer Träume, wie unserer Gedanken. - Voltaire

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram